Mentifar (Memantine Hydrochloride)

Memantine works as a non‑competitive antagonist of the NMDA receptor. By blocking the receptor’s ion channel, it limits excessive calcium entry caused by overstimulation with glutamate, thereby protecting neurons from excitotoxic damage that contributes to cognitive decline.

The dosage of Mentifar is determined by the prescribing clinician based on the patient’s clinical condition, renal function and tolerability. Physicians typically start with a low dose and titrate upward as needed, following approved prescribing information.

Safety data for memantine in pregnancy and lactation are limited. It should only be used if the potential benefit to the mother outweighs any possible risk to the fetus or infant, and the decision should be made by a qualified healthcare professional.

To order Mentifar, submit an enquiry on the product page at gnhindia.com, specifying the required quantity. GNH India works with hospitals, pharmacies and procurement teams worldwide, verifies trade or institutional credentials, and then provides pricing, availability, shipping details and any necessary import documentation.

Mentifar (memantine) belongs to the NMDA receptor antagonist class, differing from cholinesterase inhibitors such as donepezil. While cholinesterase inhibitors increase acetylcholine levels, memantine reduces glutamate‑mediated excitotoxicity. The choice of therapy depends on disease stage, patient tolerance and physician assessment.

Mentifar should be stored below 25 °C in a dry place. Keep the tablets in the original packaging, protect them from moisture and direct sunlight, and ensure they are out of reach of children.

Mentifar is taken orally, usually once daily with or without food, as directed by the prescribing physician. Swallow the tablet whole with a glass of water; do not crush or chew unless specifically instructed.

Serious risks include the potential for seizures, severe allergic reactions such as rash or angioedema, and rare but life‑threatening skin conditions like Stevens‑Johnson syndrome. Patients should seek immediate medical attention if they experience any of these symptoms.

Mentifar is contraindicated in patients with known hypersensitivity to memantine or any component of the formulation. Caution is also advised for individuals with severe renal impairment, uncontrolled hypertension, or those taking other NMDA antagonists.